Grifols, ES0171996087

Grifols stock gains 2.06 percent as profit jumps

Published on 09/28/2026 at 13:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols stock traded at EUR 9.59 on September 27, 2026, after first-half profit increased 28.7 percent. Reuters also covered a Canadian plasma license issue.

Isometrische 3D-Grafik der Plasma-Wertschöpfungskette von Spende bis Medikament — Isometrische 3D-Illustration zeigt die Wertschöpfungskette von der Plasmaspende bis zum Medikament bei Grifols S.A. ES0171996087, Illustration mit AI erstellt.

Grifols stock (ISIN ES0171996087) was trading at EUR 9.59 on BME on September 27, 2026, up 2.06 percent from the prior close of EUR 9.40. The move came as the plasma medicines group entered a fresh investor debate over profitability, cash generation and operational risk.

Canadian license issue enters view

According to Reuters on September 24, 2026, Grifols said Health Canada's suspension of the license to collect plasma at its Taylor Avenue facility in Winnipeg had no impact on ongoing operations.

The statement matters because plasma collection is central to Grifols' supply chain. The company develops and manufactures therapies derived from human plasma, including immunoglobulins, albumin and alpha-1 antitrypsin, making collection capacity a direct operating consideration.

Profit growth outpaces revenue

Grifols reported first-half 2026 revenue of EUR 3.6 billion, up 2.6 percent at constant currency, while net profit increased 28.7 percent to EUR 227 million. Grifols published those figures on July 28, 2026.

The margin and cash-flow picture adds detail to that comparison. Adjusted EBITDA reached EUR 854 million in the first half, up 2.4 percent at constant currency, with an adjusted EBITDA margin of 23.9 percent; free cash flow before mergers and acquisitions was positive at EUR 91 million, an EUR 103 million improvement from the prior-year period.

For investors, the combination is more important than the revenue rate alone: earnings and cash generation improved faster than sales. Management also maintained its full-year adjusted EBITDA margin target of at least 25 percent, keeping execution and deleveraging central to the valuation discussion.

Stock value and trading snapshot

Grifols had a market capitalization of EUR 5.8 billion on September 27, 2026, while reported volume reached 963,161 shares. The stock's reference price of EUR 9.59 was EUR 0.19 above the previous close, giving the session a clearly positive direction.

The market picture still carries a risk counterweight. The Canadian license issue was described as operationally contained by the company, but any disruption to plasma collection can affect supply costs, production planning and the pace of margin improvement.

Profitability remains the key checkpoint

Grifols stock was trading at EUR 9.59 on BME on September 27, 2026. The next valuation test is whether the first-half improvement in net profit and free cash flow can continue while the company protects plasma supply and reaches its 25 percent adjusted EBITDA margin target.